Literature DB >> 22463796

Osteoclasts: malefactors of disease and targets for treatment.

James R Edwards1, Megan M Weivoda.   

Abstract

The osteoclast represents one of the most highly specialized cells within the human body, which operates within a microenvironment of diverse cellular populations and matrix proteins. Moreover, the osteoclast directly effects and is affected by these surroundings in a delicate relationship of cellular differentiation, bone resorption, and controlled apoptosis. The result is the maintenance of adequate bone mass throughout life. Unsurprisingly, disturbances within this environment or the molecular regulation of normal osteoclast biology has profound effects on skeletal homeostasis and crippling physical manifestations. This review will summarize current literature describing normal and pathological osteoclast biology and highlight the benefits of osteoclast-targeted therapy to combat skeletal disorders.

Entities:  

Mesh:

Year:  2012        PMID: 22463796

Source DB:  PubMed          Journal:  Discov Med        ISSN: 1539-6509            Impact factor:   2.970


  9 in total

1.  [Effect of zoledronate on the osteoclast adhesion and gene expression of integrin α(v) and β3].

Authors:  Lin Jueshan; Dong Wei; Xu Chunfeng; Sun Hong; Feng Xiaojie; Qi Mengchun
Journal:  Hua Xi Kou Qiang Yi Xue Za Zhi       Date:  2014-12

2.  EB1 levels are elevated in ascorbic Acid (AA)-stimulated osteoblasts and mediate cell-cell adhesion-induced osteoblast differentiation.

Authors:  Sofia Pustylnik; Cara Fiorino; Noushin Nabavi; Tanya Zappitelli; Rosa da Silva; Jane E Aubin; Rene E Harrison
Journal:  J Biol Chem       Date:  2013-06-05       Impact factor: 5.157

3.  Ferulic acid impairs osteoclast fusion and exacerbates survival of mature osteoclasts.

Authors:  Travers Sagar; Mpho Rantlha; Marlena C Kruger; Magdalena Coetzee; Vishwa Deepak
Journal:  Cytotechnology       Date:  2016-07-23       Impact factor: 2.058

4.  Sinomenine induces apoptosis in RAW 264.7 cell-derived osteoclasts in vitro via caspase-3 activation.

Authors:  Long-gang He; Xiang-lian Li; Xiang-zhou Zeng; Heng Duan; Song Wang; Lin-sheng Lei; Xiao-juan Li; Shu-wen Liu
Journal:  Acta Pharmacol Sin       Date:  2013-12-23       Impact factor: 6.150

Review 5.  Development of Bone Targeting Drugs.

Authors:  Molly Stapleton; Kazuki Sawamoto; Carlos J Alméciga-Díaz; William G Mackenzie; Robert W Mason; Tadao Orii; Shunji Tomatsu
Journal:  Int J Mol Sci       Date:  2017-06-23       Impact factor: 5.923

6.  Fluorine-contained hydroxyapatite suppresses bone resorption through inhibiting osteoclasts differentiation and function in vitro and in vivo.

Authors:  Shibo Liu; Hao Zhou; Hanghang Liu; Huanzhong Ji; Wei Fei; En Luo
Journal:  Cell Prolif       Date:  2019-04-10       Impact factor: 6.831

7.  Identification of osteoclast-osteoblast coupling factors in humans reveals links between bone and energy metabolism.

Authors:  Megan M Weivoda; Chee Kian Chew; David G Monroe; Joshua N Farr; Elizabeth J Atkinson; Jennifer R Geske; Brittany Eckhardt; Brianne Thicke; Ming Ruan; Amanda J Tweed; Louise K McCready; Robert A Rizza; Aleksey Matveyenko; Moustapha Kassem; Thomas Levin Andersen; Adrian Vella; Matthew T Drake; Bart L Clarke; Merry Jo Oursler; Sundeep Khosla
Journal:  Nat Commun       Date:  2020-01-07       Impact factor: 14.919

8.  Guizhi-Shaoyao-Zhimu decoction attenuates bone erosion in rats that have collagen-induced arthritis via modulating NF-κB signalling to suppress osteoclastogenesis.

Authors:  Shu-Jun Wei; Qing Zhang; Yong-Jing Xiang; Lan-Yu Peng; Wei Peng; Qiang Ren; Yong-Xiang Gao
Journal:  Pharm Biol       Date:  2021-12       Impact factor: 3.503

Review 9.  Dissecting the role of bone marrow stromal cells on bone metastases.

Authors:  Denise Buenrostro; Serk In Park; Julie A Sterling
Journal:  Biomed Res Int       Date:  2014-06-26       Impact factor: 3.411

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.